Novel methods of modulating cellular interactions in sickle cell disease.
| Agent . | Mechanism . | Reference . |
|---|---|---|
| Abbreviations: vWF, von Willebrand factor; NOS, nitric oxide synthase | ||
| Sulfasalazine | NF-κB inhibitor; decreases endothelial activation | 19,20 |
| αVβ3 antibodies | Block vWF and thrombospondin mediated adherence | 21 |
| Anionic polysaccharides | Inhibit thrombospondin-mediated adhesion to the endothelium | 22 |
| Oxygenated perflubron- based fluorocarbon emulsion | Increase O2 delivery and unsickle deformed cells | 23 |
| IgG | Inhibit WBC adherence and WBC-RBC interaction | 24 |
| Heparin | Inhibits P-selectin–RBC interaction | 25 |
| Statins | Inhibit tissue factor expression; induce NOS | 26 |
| Agent . | Mechanism . | Reference . |
|---|---|---|
| Abbreviations: vWF, von Willebrand factor; NOS, nitric oxide synthase | ||
| Sulfasalazine | NF-κB inhibitor; decreases endothelial activation | 19,20 |
| αVβ3 antibodies | Block vWF and thrombospondin mediated adherence | 21 |
| Anionic polysaccharides | Inhibit thrombospondin-mediated adhesion to the endothelium | 22 |
| Oxygenated perflubron- based fluorocarbon emulsion | Increase O2 delivery and unsickle deformed cells | 23 |
| IgG | Inhibit WBC adherence and WBC-RBC interaction | 24 |
| Heparin | Inhibits P-selectin–RBC interaction | 25 |
| Statins | Inhibit tissue factor expression; induce NOS | 26 |